Table 2.

Efficacy results of prexasertib in patients with ovarian, fallopian, and peritoneal cancer

Parameter	Cohort 1: Platinum resistant, BRCA-wildtype with ≥3 prior lines of therapy N=53	Cohort 2: Platinum resistant, BRCA-wildtype with <3 prior lines of therapy N=46	Cohort 3: Platinum resistant, BRCA-mutated with prior PARP inhibitor therapy N=41	Cohort 4: Platinum refractory with any number of prior lines of therapy N=29
Best overall response, n (%) (95% CI)
CR	0 (0.0) (0.0, 6.7)	1 (2.2) (0.1, 11.5)	0 (0.0) (0.0, 8.6)	0 (0.0) (0.0, 11.9)
PR	6 (11.3) (4.3, 23.0)	5 (10.9) (3.6, 23.6)	5 (12.2) (4.1, 26.2)	2 (6.9) (0.8, 22.8)
SD	33 (62.3) (47.9, 75.2)	24 (52.2) (36.9, 67.1)	17 (41.5) (26.3, 57.9)	13 (44.8) (26.4, 64.3)
PD	9 (17.0) (8.1,29.8)	15 (32.6) (19.5,48.0)	15 (36.6) (22.1,53.1)	11 (37.9) (20.7,57.7)
ORR (CR/PR), n (%) (95% CI)	6 (11.3) (4.3, 23.0)	6 (13.0) (4.9, 26.3)	5 (12.2) (4.1, 26.2)	2 (6.9) (0.8, 22.8)
DCR (CR+PR+Stable disease persisting≥4 months), n (%) (95% CI)	24 (45.3) (31.6, 59.6)	15 (32.6) (19.5, 48.0)	13 (31.7) (18.1,48.1)	9 (31. 0) (15.3, 50.8)
DoR, median months (95% CI); patients censored (%)a	8.6 (5.6, NE); 0 (0.0)	3.8 (2.8, NE); 1 (16.7)	5.6 (3.7, NE); 0 (0.0)	5.3 (5.1, NE); 0 (0.0)
PFS, median months (95% CI); patients censored (%)	3.9 (3.7, 5.7); 6 (11.3)	3.7 (3.1, 4.7); 4 (8.7)	3.6 (1.9, 3.9); 4 (9.8)	3.7 (1.8, 4.7); 4 (13.8)
OS, median months (95% CI); Patients censored (%)	13.0 (7.5, 19.3); 18 (34.0)	14.3 (11.8, 16.5); 12 (26.1)	11.1 (7.2, 16.4); 12 (29.3)	8.2 (6.2, 11.9); 4 (13.8)

^aThe total ‘N’ varied (N=19); Cohort 1 n=6; Cohort 2 n=6; Cohort 3 n=5; Cohort 4 n=2

Abbreviations: BRCA, breast cancer gene; CI, confidence interval; CR, complete response; DCR, disease control rate; DoR, duration of response; N = number of patients in the population; n = number of patients in the specified category; NE = not evaluable; OS, overall survival; PD, progressive disease; PFS, progression-free survival; PR, partial response; SD, stable disease